Show Me the Value: DFARS Proposes Rule on Market Research and Value-Based Price Reasonableness Determination
Client Alert | 1 min read | 10.04.19
On September 26, 2019, the DoD issued a proposed rule to implement Sections 871 and 872 of the NDAA for FY 2017, both of which address price reasonableness when acquiring commercial items.
To implement Section 871, the proposed rule revises DFARS 212.209(a) to reflect Section 871’s focus that agencies must conduct market research to support the determination of price reasonableness for commercial items (the current version simply indicates that market research must be used, where appropriate, to inform price reasonableness determinations). The proposed rule also would add a provision directing contracting officers to use the information submitted under DFARS 234.7002(d) when acquiring major weapon systems as commercial items; or, in the case of other items, other relevant information as described in DFARS 212.209.
To implement Section 872, the proposed rule would revise DFARS subpart 234.70, which addresses the acquisition of major weapon systems as commercial items, by adding a new paragraph permitting offerors to submit information or analysis relating to the value of a commercial item, to aid in the determination of the reasonableness of the item’s price. Relatedly, the proposed rule adds the definition of “value analysis” to clarify that such reasonableness determination is focused on ensuring optimum value based on objective evaluation of the function of the product and its related costs.
Comments are due on or before November 25, 2019.
Contacts
Insights
Client Alert | 5 min read | 12.12.25
Eleventh Circuit Hears Argument on False Claims Act Qui Tam Constitutionality
On the morning of December 12, 2025, the Eleventh Circuit heard argument in United States ex rel. Zafirov v. Florida Medical Associates, LLC, et al., No. 24-13581 (11th Cir. 2025). This case concerns the constitutionality of the False Claims Act (FCA) qui tam provisions and a groundbreaking September 2024 opinion in which the United States District Court for the Middle District of Florida held that the FCA’s qui tam provisions were unconstitutional under Article II. See United States ex rel. Zafirov v. Fla. Med. Assocs., LLC, 751 F. Supp. 3d 1293 (M.D. Fla. 2024). That decision, penned by District Judge Kathryn Kimball Mizelle, was the first success story for a legal theory that has been gaining steam ever since Justices Thomas, Barrett, and Kavanaugh indicated they would be willing to consider arguments about the constitutionality of the qui tam provisions in U.S. ex rel. Polansky v. Exec. Health Res., 599 U.S. 419 (2023). In her opinion, Judge Mizelle held (1) qui tam relators are officers of the U.S. who must be appointed under the Appointments Clause; and (2) historical practice treating qui tam and similar relators as less than “officers” for constitutional purposes was not enough to save the qui tam provisions from the fundamental Article II infirmity the court identified. That ruling was appealed and, after full briefing, including by the government and a bevy of amici, the litigants stepped up to the plate this morning for oral argument.
Client Alert | 8 min read | 12.11.25
Director Squires Revamps the Workings of the U.S. Patent Office
Client Alert | 8 min read | 12.10.25
Creativity You Can Use: CJEU Clarifies Copyright for Applied Art
Client Alert | 4 min read | 12.10.25
Federal Court Strikes Down Interior Order Suspending Wind Energy Development
